MedWatch

Novo CEO Lars Fruergaard Jørgensen hopes for Eli Lilly's future success

US firm Eli Lilly will hopefully keep up its great performance in the lucrative GLP-1 market, says Novo Nordisk CEO Lars Fruergaard Jørgensen.

Novo Nordisk CEO Lars Fruergaard Jørgensen | Photo: Stine Bidstrup/ERH

We love it the way it is right now, and for this reason, we would love it if things continued in the same way. This sentiment captures the mindset of Danish pharmaceutical firm Novo Nordisk's CEO Lars Fruergaard Jørgensen.

"I hope Eli Lilly will be up for the competition and do well. I don't see either of us taking over complete dominance of the market by having a hugely differentiated product," says Fruergaard Jørgensen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs